Chinese patent medicines for lupus nephritis in adults: a multiple-treatment meta-analysis

Background Standard drug treatments (SDTs) have suboptimal responses in some lupus nephritis (LN) patients, leading to end-stage kidney disease (ESKD). Chinese patent medicines (CPMs) have long been used as adjuvant therapies to SDTs to improve efficacy and alleviate adverse effects. Therefore, exploring the relative effectiveness of CPMs as adjuvant interventions is clinically significant for LN management. This study aims to evaluate the relative effectiveness of CPMs as an adjunct to SDTs, and examine moderating factors and potential reporting bias. Methods We systematically searched nine electronic databases (PubMed, Embase, Cochrane Library, Web of Science, Scopus, CNKI, Wanfang, VIP, and SinoMed), a trial registry (ClinicalTrials.gov), and regulatory websites from inception to February 2025 for RCTs on CPMs combined with SDTs in adult LN patients. A multiple treatment meta-analysis (MTMA) synthesizing direct and indirect evidence used random-effects models and was analyzed with Stata/MP and R. Outcomes included complete renal remission (CRR), partial renal remission (PRR), SLE Disease Activity Index 2000 (SLEDAI-2K)score, serum creatinine (SCr), urinary protein quantification, absolute risk difference (ARD), and number needed to treat (NNT). Key results Forty-eight RCTs met the criteria, enrolling 3,726 LN patients. The evidence network was star-shaped (every trial compared a Chinese patent medicine plus SDT with SDT alone), so all between-CPM rankings reported below rest on purely indirect comparison. MTMA showed that, compared to SDT, combined treatment with CPMs had better overall therapeutic efficacy. Among them, Yishenyangyinheji (YSYY) plus SDT and Huobahuagen Tablets (HBHGP) plus SDT ranked first for CRR and PRR, respectively; however, the PRR benefit was not robust to trim-and-fill adjustment for small-study effects (adjusted RR 0.956, 95% CI 0.858–1.065), and the top PRR ranking was sensitive to node modelling (CRR RR = 2.37, 95% CI: 1.60–3.53, surface under the cumulative ranking curve (SUCRA) = 89.80%, ARD = 0.356, 95% CI: 0.140–0.689, NNT = 2.80, 95% CI: 1.45–7.14; PRR RR = 1.60, 95% CI: 1.02–2.51, SUCRA = 96.00%, ARD = 0.210, 95% CI: 0.007–0.530, NNT = 4.80, 95% CI: 1.90–142.90). For the SLEDAI-2K score, Total Glucosides of White Paeony (TGP) plus SDT ranked first on indirect comparison (SMD = −3.89, 95% CI: −4.93 to −2.84, SUCRA = 99.20%).Langchuangpingkeli (LCJKL) and Tripterygium glycoside tablets (TGT) marginally improved SCr reduction and 24-hour TP, but without statistical significance. Conclusions CPMs plus SDT for LN generally appeared superior to SDT alone. In purely indirect comparisons within a star-shaped network, YSYY plus SDT and HBHGP plus SDT ranked first for CRR and PRR, respectively; the PRR signal was not robust to adjustment for small-study effects and was sensitive to node modelling. GRADE certainty was low for the CRR signal and very low for the PRR signal, and all between-CPM rankings are hypothesis-generating. Given only small, single-center Chinese trials, adequately powered, multicenter trials with standardized long-term safety assessment are needed before any adjuvant CPM can be recommended. Systematic review registration https://inplasy.com/ , identifier INPLASY202520059.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1875808
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Chinese patent medicines for lupus nephritis in adults: a multiple-treatment meta-analysis

Min Wen, Jing Chen, Liquan yuan, Sini Li et al.
1 links
Frontiers in Immunology
Systemic Lupus Erythematosus Research
article

Chinese patent medicines for lupus nephritis in adults: a multiple-treatment meta-analysis

Min Wen, Jing Chen, Liquan yuan, Sini Li, Aijuan Lu, Ciyan Peng, Qin Zhang
article en

Abstract

Background Standard drug treatments (SDTs) have suboptimal responses in some lupus nephritis (LN) patients, leading to end-stage kidney disease (ESKD). Chinese patent medicines (CPMs) have long been used as adjuvant therapies to SDTs to improve efficacy and alleviate adverse effects. Therefore, exploring the relative effectiveness of CPMs as adjuvant interventions is clinically significant for LN management. This study aims to evaluate the relative effectiveness of CPMs as an adjunct to SDTs, and examine moderating factors and potential reporting bias. Methods We systematically searched nine electronic databases (PubMed, Embase, Cochrane Library, Web of Science, Scopus, CNKI, Wanfang, VIP, and SinoMed), a trial registry (ClinicalTrials.gov), and regulatory websites from inception to February 2025 for RCTs on CPMs combined with SDTs in adult LN patients. A multiple treatment meta-analysis (MTMA) synthesizing direct and indirect evidence used random-effects models and was analyzed with Stata/MP and R. Outcomes included complete renal remission (CRR), partial renal remission (PRR), SLE Disease Activity Index 2000 (SLEDAI-2K)score, serum creatinine (SCr), urinary protein quantification, absolute risk difference (ARD), and number needed to treat (NNT). Key results Forty-eight RCTs met the criteria, enrolling 3,726 LN patients. The evidence network was star-shaped (every trial compared a Chinese patent medicine plus SDT with SDT alone), so all between-CPM rankings reported below rest on purely indirect comparison. MTMA showed that, compared to SDT, combined treatment with CPMs had better overall therapeutic efficacy. Among them, Yishenyangyinheji (YSYY) plus SDT and Huobahuagen Tablets (HBHGP) plus SDT ranked first for CRR and PRR, respectively; however, the PRR benefit was not robust to trim-and-fill adjustment for small-study effects (adjusted RR 0.956, 95% CI 0.858–1.065), and the top PRR ranking was sensitive to node modelling (CRR RR = 2.37, 95% CI: 1.60–3.53, surface under the cumulative ranking curve (SUCRA) = 89.80%, ARD = 0.356, 95% CI: 0.140–0.689, NNT = 2.80, 95% CI: 1.45–7.14; PRR RR = 1.60, 95% CI: 1.02–2.51, SUCRA = 96.00%, ARD = 0.210, 95% CI: 0.007–0.530, NNT = 4.80, 95% CI: 1.90–142.90). For the SLEDAI-2K score, Total Glucosides of White Paeony (TGP) plus SDT ranked first on indirect comparison (SMD = −3.89, 95% CI: −4.93 to −2.84, SUCRA = 99.20%).Langchuangpingkeli (LCJKL) and Tripterygium glycoside tablets (TGT) marginally improved SCr reduction and 24-hour TP, but without statistical significance. Conclusions CPMs plus SDT for LN generally appeared superior to SDT alone. In purely indirect comparisons within a star-shaped network, YSYY plus SDT and HBHGP plus SDT ranked first for CRR and PRR, respectively; the PRR signal was not robust to adjustment for small-study effects and was sensitive to node modelling. GRADE certainty was low for the CRR signal and very low for the PRR signal, and all between-CPM rankings are hypothesis-generating. Given only small, single-center Chinese trials, adequately powered, multicenter trials with standardized long-term safety assessment are needed before any adjuvant CPM can be recommended. Systematic review registration https://inplasy.com/ , identifier INPLASY202520059.

Frontiers in ImmunologyVol. 17
Central South University (CN), Hunan University of Traditional Chinese Medicine (CN), First Affiliated Hospital of Hunan University of Traditional Chinese Medicine (CN), Second Xiangya Hospital of Central South University (CN)
Good health and well-being
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon